evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Intervention not reported

Economic data · peri‐ or postmenopausal women with type 1 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).

1 finding from 1 review

Intervention not reported

Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus

The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).

1 finding from 1 review

Intervention not reported

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events 3. Severe hypoglycaemia a. Intervention vs placebo [1a. 24 weeks] [2a. 24 weeks to 56 weeks] b. Intervention vs metformin [1b. 6 months to 4 years] [2b. 24 weeks to 4 years] [... · participants with type 2 diabetes mellitus

The intervention showed no clear difference in adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).

1 finding from 1 review

Intervention not reported

Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).

1 finding from 1 review

Intervention not reported

Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review

Intervention not reported

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus

The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).

1 finding from 1 review

Intervention not reported

Cardiovascular mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

The intervention may leads to higher cardiovascular mortality a. Intervention vs placebo [30 weeks to… (low certainty).

1 finding from 1 review